Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Fig. 1

a-b Treatment of 4 T1 TNBC xenograft model with vehicle control, RX-5902 (60 mg/kg), anti-mouse PD-1 (100 μg/mouse) or the combination. TGI compared to vehicle: RX-5902 60 (TGI = 44%; p = 0.007), anti-mouse-PD-1 (TGI = 21%; p = 0.173), combination (TGI = 61%; p = 0.001). Combination compared to RX-5902 alone and anti-mouse-PD-1 alone (p = 0.032 and p = 0.001, respectively). c-d Treatment of 4 T1 TNBC xenograft model with vehicle control, RX-5902 (35 mg/kg), RX-5902 (75 mg/kg), RX-5902 (35 mg/kg) plus anti-CTLA-4 (5 mg/kg) or RX-5902 (75 mg/kg) plus anti-CTLA-4 (5 mg/kg) resulted in TGI at day 25 compared to vehicle control: TGI 35%, p = 0.006; TGI 76%, p < 0.001; TGI 67%, p < 0.001, TGI 76%, p < 0.001. Combination of RX-5902 (35 mg/kg) plus anti-CTLA-4 (5 mg/kg) compared to RX-5902 alone (p = 0.007). * p < 0.05, **p < 0.01

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us